Medical News

Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children –⁠ Results of the TERIKIDS Study

1. 6. 2022 Source: Multiple Sclerosis

Therapeutic options for multiple sclerosis in the pediatric population are limited. However, in June 2021, teriflunomide was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10–17 years in the European Union. The basis for this registration was the favorable results of the TERIKIDS study, which we summarize below. Teriflunomide thus became the first oral medication for 1st line treatment of RRMS in children and adolescents within the EU.

Cost-Effectiveness of Eletriptan in Acute Migraine Treatment

Even in a market dominated by generics, eletriptan 40 mg is among the most clinically effective and cost-efficient triptans for the acute treatment of migraine attacks. This was demonstrated by a…

1. 6. 2022 Source: Treatment of Severe Migraine

Doc. Petr Dulíček: Physical activity in hemophiliacs? Today it is a reality -⁠ just don't be afraid!

Thanks to modern treatment, the lives of hemophiliacs are becoming more active. Patients today can engage in most sports activities. On the contrary, avoiding physical activity carries the risk of…

30. 5. 2022 Source: Hemophilia with Movement

Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population

Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does...

30. 5. 2022 Source: Hemophilia with Movement

Tofacitinib Helps Restore Intestinal Epithelial Barrier

The Janus kinase inhibitor (JAKi) tofacitinib was relatively recently approved for the treatment of ulcerative colitis, but its effect on the intestinal epithelium remains a subject of research. The…

30. 5. 2022 Source: Intestinal Inflammations

Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis –⁠ Interim Results of the OPAL Balance Study

Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the treatment of active psoriatic arthritis in adult patients. The efficacy and safety of tofacitinib in…

30. 5. 2022 Source: Arthritis

Cardiovascular Safety of Tofacitinib in Real-World Clinical Practice –⁠ Results of the STAR-RA Study

Recent results from the ORAL Surveillance clinical trial have raised concerns about the cardiovascular adverse effects of tofacitinib in patients with rheumatoid arthritis. A comprehensive analysis…

29. 5. 2022 Source: Arthritis

Maintenance of Remission with Tofacitinib in Patients with UC –⁠ Results of the OCTAVE Open Study

Tofacitinib is indicated for the treatment of ulcerative colitis (UC) in cases where conventional treatment or monoclonal antibodies do not yield sufficient results. Key benefits of this medication…

28. 5. 2022 Source: Intestinal Inflammations

Indication of Bilastine in Specific Patient Groups −⁠ Practical Tips for Clinical Practice

Bilastine is a non-sedating H1-antihistamine, which is very well tolerated by patients. It can be indicated in the therapy of allergic diseases in both pediatric and adult populations. What are the…

24. 5. 2022 Source: Allergic Reactions

Bilastine in the treatment of allergic rhinitis –⁠ meta-analysis shows advantage of lower somnolence

A newly published systematic review and meta-analysis evaluate the efficacy and safety of bilastine in the treatment of allergic rhinitis (AR), which includes symptoms of common rhinitis and allergic…

24. 5. 2022 Source: Allergic Reactions

Need for Early Intervention in COPD −⁠ A Suitable Time for Mucolytic Treatment

Chronic Obstructive Pulmonary Disease (COPD) ranks third among the leading causes of morbidity and mortality worldwide, with more than 210 million people expected to be affected by 2030. While…

24. 5. 2022 Source: Cough Therapy

What Did 3 Years of Data from the Czech National COPD Database Reveal?

In December of last year, the Czech multicenter research database on COPD was completed. This was an extensive 5-year project in which researchers included 784 patients with significant chronic…

24. 5. 2022 Source: Cough Therapy

COPD is Treated Differently Across Europe –⁠ What Could Be the Reasons for This Variability?

As part of this year's Hradec Pneumological Days (HPD 2022), the head of the Pulmonary Clinic at Charles University Faculty of Medicine and University Hospital Hradec Králové, Assoc. Prof. Vladimír…

24. 5. 2022 Source: Cough Therapy

Prolonged Course of Metastatic Stomach Cancer with Long-term Stabilization –⁠ Case Report

In the following case report, we present the case of a patient with a prolonged oncological disease –⁠ stomach cancer. The patient has been asymptomatic for a long time and in good performance status…

24. 5. 2022 Source: Treatment of Gastrointestinal Carcinomas

Focused on MS: Statistics Are Boring, But They Have Valuable Data!

What is the prevalence of multiple sclerosis? Has the proportion of patients treated with highly effective therapy changed? We bring you the latest data from around the world and domestically.

23. 5. 2022 Source: Multiple Sclerosis

1 … 49 50 51 52 53 … 111

Back Filter by speciality

Remove filters

Popular this week